- Report
- April 2024
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- March 2024
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- January 2024
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- January 2022
- 419 Pages
Global
From €9169EUR$9,500USD£7,866GBP
- Report
- November 2021
- 101 Pages
Global
From €4343EUR$4,500USD£3,726GBP
- Report
- May 2021
- 50 Pages
China
From €2510EUR$2,600USD£2,153GBP
- Drug Pipelines
- April 2021
- 64 Pages
Global
€21234EUR$22,000USD£18,215GBP
- Report
- July 2018
- 33 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Report
- July 2018
- 16 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Report
- July 2018
- 17 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Report
- July 2018
- 21 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Drug Pipelines
- February 2018
- 35 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Report
- April 2023
- 156 Pages
Global
€4826EUR$5,000USD£4,140GBP
- Report
- April 2023
- 114 Pages
Global
€3378EUR$3,500USD£2,898GBP
- Report
- July 2018
- 11 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Report
- March 2023
- 147 Pages
Global
From €5790EUR$5,999USD£4,967GBP
Spiriva is a respiratory drug used to treat chronic obstructive pulmonary disease (COPD). It is a long-acting bronchodilator that works by relaxing the muscles in the airways, allowing more air to flow in and out of the lungs. It is available in both capsule and inhaler form. Spiriva is typically prescribed to patients with COPD who have difficulty breathing due to narrowing of the airways. It is also used to prevent flare-ups of COPD symptoms.
Spiriva is a popular drug in the respiratory market, with many generic and branded versions available. It is often prescribed in combination with other medications to treat COPD. It is also used to treat asthma, although it is not approved for this indication.
The companies in the Spiriva market include Boehringer Ingelheim, Pfizer, GlaxoSmithKline, Merck, and AstraZeneca. Show Less Read more
